Omega Mediation Group

Omega Therapeutics is a clinical-stage biotechnology company pioneering a new class of DNA-sequence-specific epigenomic medicines. The company's proprietary OMEGA platform leverages "Omega Epigenomic Controllers" to programmatically engineer the expression of genes without altering the underlying DNA sequence. Their lead candidate, OTX-2002, is a first-in-class epigenomic controller designed to downregulate the MYC oncogene in patients with hepatocellular carcinoma. Omega's approach targets the "Insulated Neighborhoods" of the genome to treat a wide range of diseases, including oncology, multigenic diseases, and regenerative medicine.